Product Description
Trimipramine does not reduce, but rather increases, rapid eye movement sleep. It stimulates nocturnal prolactin secretion and inhibits nocturnal cortisol secretion and may act at the level of the hypothalamus on corticotropin-releasing hormone secretion. Trimipramine is of particular value in depressed patients with insomnia, and it has been shown to be effective in the therapy of primary insomnia. s the pharmacological profile indicates, and an open clinical study has shown, trimipramine might also be active as an antipsychotic. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/8863001/)
Mechanisms of Action: NRI Inhibitor, SRI Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Bangladesh | Canada | Chile | Colombia | Egypt | Finland | France | Germany | Hong Kong | India | Ireland | Italy | Malta | Morocco | New Zealand | Norway | Pakistan | Peru | Philippines | Portugal | South Africa | Spain | Sweden | Switzerland | Taiwan | Tunisia | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|